ALNY News and Press, Alnylam Pharmaceuticals Inc. From 03/22/23

2023-03-22 08:51:49 ET Summary Shares of infectious disease medicines concern Vir Biotechnology are trading at only a $6-$7 per share premium to cash as the revenue from its Covid-19 medication dries up. The company has three compounds undergoing evaluation as both monotherapies a...

2023-03-13 23:58:45 ET Summary Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Silence Therapeutics is a de-risked investment opportunity with significant potential upside, supported by its robust pipeline, strateg...

2023-03-09 07:37:30 ET Alnylam Pharmaceuticals ( NASDAQ: ALNY ) and Medison Pharma have decided to expand their existing collaboration for RNA interference therapeutics to several Central and Eastern European countries, the companies announced Thursday. The multi-regional ...

Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics Canada NewsWire ZUG, Switzerland , March 9, 2023 /CNW/ -- Alnylam Pharmaceuticals, Inc. (Na...

– Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of D...

Summary Merck is an American biopharma powerhouse that has generated consistent compounding growth, increasing its top line and EPS. Merck expects to deploy capital through strategic small bolt-on acquisitions, which we are a big fan of, rather than rampant big indiscriminate acquisitio...

Summary Alnylam's fourth quarter results were consistent with recently updated guidance, while guidance for FY'23 was modestly weaker for product revenue and more significantly weaker for collaboration revenue. The FDA will conduct an advisory panel meeting for the company's application...

Summary Regeneron has a respectable portfolio of commercialized medicines and is working on potentially transformative new technologies for immuno-oncology. Their collaborative energy is strong and the medium-term looks good, but a lot of their future hinges on emerging biotechnological...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) is down 4% in Thursday afternoon trading as the company's 2023 product revenue estimate range left the Street underwhelmed. For 2023, the company is projecting net product revenue of $1.2B-1.285B. In 2022, Alnylam recorded product reven...

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2022 Earnings Conference Call February 23, 2023, 08:30 AM ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga Ta...